SLC1A5 and acute myeloid leukemia: Given the significantly higher expression of glutamine transporters LAT1, LAT3, and ASCT2 (SLC1A5) in AML cells versus normal cells, the antileukemic effect of inhibiting these transporters was tested [129-131].